Technical Analysis for PMCB - PharmaCyte Biotech, Inc.

Grade Last Price % Change Price Change
D 2.29 -0.43% -0.01
PMCB closed down 4.96 percent on Tuesday, January 18, 2022, on approximately normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical PMCB trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish -0.43%
Lower Bollinger Band Walk Weakness -0.43%
New 52 Week Low Weakness -0.43%
Lower Bollinger Band Touch Weakness -0.43%
Oversold Stochastic Weakness -0.43%
Bullish Engulfing Bullish -5.37%
Stochastic Buy Signal Bullish -5.37%
Lower Bollinger Band Walk Weakness -5.37%
Outside Day Range Expansion -5.37%
Lower Bollinger Band Touch Weakness -5.37%
Older End-of-Day Signals for PMCB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Lower Bollinger Band about 1 hour ago
Down 2 % about 1 hour ago
Lower Bollinger Band Support about 2 hours ago
Down 1% about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


PharmaCyte Biotech, Inc. Description

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.


Sector: Healthcare
Industry: Biotechnology

Is PMCB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.98
52 Week Low 2.17
Average Volume 368,088
200-Day Moving Average 0.00
50-Day Moving Average 2.58
20-Day Moving Average 2.52
10-Day Moving Average 2.45
Average True Range 0.15
ADX 8.98
+DI 15.70
-DI 20.83
Chandelier Exit (Long, 3 ATRs) 2.37
Chandelier Exit (Short, 3 ATRs) 2.62
Upper Bollinger Bands 2.76
Lower Bollinger Band 2.28
Percent B (%b) 0.04
BandWidth 18.99
MACD Line -0.07
MACD Signal Line -0.04
MACD Histogram -0.0205
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.60
Resistance 3 (R3) 2.59 2.48 2.55
Resistance 2 (R2) 2.48 2.40 2.49 2.53
Resistance 1 (R1) 2.39 2.36 2.34 2.40 2.52
Pivot Point 2.28 2.28 2.25 2.29 2.28
Support 1 (S1) 2.19 2.20 2.14 2.20 2.08
Support 2 (S2) 2.08 2.16 2.09 2.07
Support 3 (S3) 1.99 2.08 2.05
Support 4 (S4) 2.00